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matic diseases is a major challenge. Therapy with
antiinflammatory drugs help relieve pain but
appear to have limited, if any, success in altering
the progression of joint destruction. Thus, novel
strategies for treatment appear warranted [1, 2].
Our laboratory is exploring the concept of gene
transfer into synovial fibroblasts as a means to
inhibit the degradation of hyaline cartilage. We
are following three strategies:
(1) The transfer of protective genes regulating
the e#ect of cytokines. These studies are in
collaboration with Chris Evans and Paul
Robbins from the University of Pittsburgh,
Pennsylvania [3, 4].
(2) The transfer of ribozymes cleaving the mRNA
of matrix-degrading enzymes collagenase
(MMP-I) and cathepsins B and L in col-
laboration with Wolfgang Zacharias at the
University of Alabama at Birmingham.
(3) The transfer of genes inhibiting signaling
mechanisms of the Ras-Raf-MAPK cascade in
the activation of synovial fibroblasts. These
studies are carried out in cooperation with
Michael Nawrath in Karin Mo¨lling’s Institute
for Virology at the University Hospital in
Zu¨rich [5].
The SCID mouse model has served as an useful
model in studying molecular and cellular mech-
anisms of rheumatoid joint destruction [6]. It has
also served to explore the feasibility of new
approaches to therapy. In this model, we trans-
ferred the genes of interleukin-1 receptor
antagonist (IL-1 Ra) [3], TNFÆ receptor p55 or of
interleukin-10 [4] into human synovial fibroblasts.
The fibroblasts were derived from patients with
rheumatoid arthritis and the transfected cells
implanted together with normal human cartilage
into SCID mice.
Neither the delivery of IL-1 Ra nor TNFÆR p55
resulted in a significant inhibition of the invasive317behavior of the cells. Interestingly, chondrocyte-
mediated cartilage degradation was markedly
reduced by using IL-1 Ra transfected RA fibro-
blasts [3]. In contrast, more than 50% of the
MFG-IL-10 retrovirus transfected RA-viral-
fibroblasts incorporated the retrovirus-delivered
gene sequences and resulted in a significant reduc-
tion of invasion. Since IL-10 is thought to inhibit
several proinflammatory and proliferative path-
ways, our results support the concept that over-
expression of IL-10 in the joint appears to be a
successful approach inhibit cartilage destruction
in RA.
In summary, the development and use of
inhibitors of synovial hyperplasia, synovial cell
attachment to cartilage and matrix-degrading
enzymes delivered by novel approaches, including
gene transfer, are major targets in our laboratory
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